Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis

Journal of Pathology

Volumn 212, Issue 2, 2007, Pages 124-133

  Minoo, Parham ^a   Moyer, M P ^b   Jass, J R ^a  

^a MCGILL UNIVERSITY   (Canada)

^b INCELL Corporation ^*  (United States)

Author keywords

BRAF V600E; CIMP; Colorectal cancer; DNA methylation; MSI H; Sessile serrated adenoma

Indexed keywords

B RAF KINASE; GLUTAMIC ACID; VALINE;

APOPTOSIS; ARTICLE; CANCER INVASION; CANCER RESISTANCE; CARCINOGENESIS; CELL LINE; CELL TRANSFORMATION; CLINICAL OBSERVATION; COLON MUCOSA; COLORECTAL TUMOR; CONTROLLED STUDY; DNA METHYLATION; EPITHELIUM CELL; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; HUMAN; HUMAN CELL; PATHOPHYSIOLOGY; PHENOTYPE; PRECANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; CELL LINE; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; COLON; COLORECTAL NEOPLASMS; CPG ISLANDS; EPITHELIAL CELLS; HUMANS; INTESTINAL MUCOSA; METHYLATION; MICROSATELLITE INSTABILITY; MODELS, BIOLOGICAL; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PHENOTYPE; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS B-RAF;

EID: 34249785078     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2160     Document Type: Article

References (63)

1. Hawk ET, Limburg PJ, Viner JL. Epidemiology and prevention of colorectal cancer. Surg Clin North Am 2002;82:905-941.
2. Boyle P, Leon ME. Epidemiology of colorectal cancer. Br Med Bull 2002;64:1-25.
3. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics 2006. CA Cancer J Clin 2006;56:106-130.
4. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. J Am Med Assoc 2005; 294:1255-1259.
5. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-532.
6. Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997;57:808-811.
7. Cunningham JM, Christensen ER, Tester DJ, Kim CY, Roche PC, Burgart LJ, et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 1998;58:3455-3460.
8. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 1999; 95:6970-6875.
9. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993;260:816-819.
10. Wright CM, Dent OF, Barker M, Newland RC, Chapuis PH, Bokey EL, et al. Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. Br J Surg 2000;87:1197-1202.
11. Kim H, Jen J, Vogelstein B, Hamilton SR. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol 1994; 145:148-156.
12. Jass JR, Do KA, Simms LA, Iino H, Wynter C, Pillay SP, et al. Morphology of sporadic colorectal cancer with DNA replication errors. Gut 1998;42:673-679.
13. Koinuma K, Shitoh K, Miyakura Y, Furukawa T, Yamashita Y, Ota J, et al. Mutations of BRAF are associated with extensive hMLH1 promoter methylation in sporadic colorectal carcinomas. Int J Cancer 2004;108:237-242.
14. Wang L, Cunningham JM, Winters JL, Guenther JC, French AJ, Boardman LA, et al. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res 2003; 63:5209-5212.
15. Kambara T, Simms LA, Whitehall VL, Spring KJ, Wynter CV, Walsh MD, et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 2004; 53:1137-1144.
16. McGivern A, Wynter CV, Whitehall VL, Kambara T, Spring KJ, Walsh MD, et al. Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer. Fam Cancer 2004;3:101-107.
17. Deng G, Bell I, Crawley S, Gum J, Terdiman JP, Allen BA, et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 2004;10:191-195.
18. Torlakovic E, Skovlund E, Snover DC, Torlakovic G, Nesland JM. Morphologic reappraisal of serrated colorectal polyps. Am J Surg Pathol 2003;27:65-81.
19. Goldstein NS, Bhanot P, Odish E, Hunter S. Hyperplastic-like colon polyps that preceded microsatellite-unstable adenocarcinomas. Am J Clin Pathol 2003;119:778-796.
20. Jass JR. Hyperplastic-like polyps as precursors of microsatellite-unstable colorectal cancer. Am J Clin Pathol 2003;119:773-775.
21. Jass JR. Serrated adenoma of the colorectum and the DNA-methylator phenotype. Nat Clin Pract Oncol 2005;2:398-405.
22. Yang S, Farraye FA, Mack C, Posnik O, O'Brien MJ. BRAF and KRAS mutations in hyperplastic polyps and serrated adenomas of the colorectum: relationship to histology and CpG island methylation status. Am J Surg Pathol 2004;28:1452-1459.
23. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer 2004;4:988-993.
24. Abuja N, Mohan AL, Li Q, Stolker JM, Herman JG, Hamilton SR, et al. Association between CpG island methylation and microsatellite instability in colorectal cancer. Cancer Res 1997; 57:3370-3374.
25. Hawkins N, Norrie M, Cheong K, Mokany E, Ku SL, Meagher A, et al. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology 2002;122:1376-1387.
26. Whitehall VL, Wynter CV, Walsh MD, Simms LA, Purdie D, Pandeya N, et al. Morphological and molecular heterogeneity within nonmicrosatellite instability-high colorectal cancer. Cancer Res 2002;62:6011-6014.
27. Park SJ, Rashid A, Lee JH, Kim SG, Hamilton SR, Wu TT. Frequent CpG island methylation in serrated adenomas of the colorectum. Am J Pathol 2003;162:815-822.
28. Dong SM, Lee EJ, Jeon ES, Park CK, Kim KM. Progressive methylation during the serrated neoplasia pathway of the colorectum. Mod Pathol 2005;18:170-178.
29. Moyer MP, Manzano LA, Merriman RL, Stauffer JS, Tanzer LR. NCM460, a normal human colon mucosal epithelial cell line. In Vitro Cell Dev Biol Anim 1996;32:315-7.
30. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. Suppression of BRAF (V599E) in human melanoma abrogates transformation. Cancer Res 2003;63:5198-5202.
31. Minoo P, Baker K, Goswami R, Chong G, Foulkes WD, Ruszkiewicz AR, et al. Extensive DNA methylation in normal colorectal mucosa in hyperplastic polyposis. Gut 2006;55:1467-1474.
32. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000;28:E32.
33. Cottrell SE, Laird PW, Sensitive detection of DNA methylation. Ann N Y Acad Sci 2003;983:120-130.
34. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Danenberg PV, Laird PW. CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res 1999; 59:2302-2306.
35. Eads CA, Lord RV, Wickramasinghe K, Long TI, Kurumboor SK, Bernstein L, et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 2001;61:3410-3418.
36. Ogino S, Kawasaki T, Brahmandam M, Cantor M, Kirkner GJ, Spiegelman D, et al. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 2006;8:209-217.
37. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109.
38. Tateyama H, Li W, Takahashi E, Miura Y, Sugiura H, Eimoto T. Apoptosis index and apoptosis-related antigen expression in serrated adenoma of the colorectum: the saw-toothed structure may be related to inhibition of apoptosis. Am J Surg Pathol 2002;26:249-256.
39. Shanmugathasan M, Jothy S. Apoptosis, anoikis and their relevance to the pathobiology of colon cancer. Pathol Int 2000;50:273-279.
40. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-454.
41. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-954.
42. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002;418:934.
43. Adnane L, Trail PA, Taylor I, Wilhelm SM. Sorafenib [BAY 43-9006, Nexavar (R)], a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 2005;407:597-612.
44. Jass JR, Whitehall VL, Young J, Leggett BA. Emerging concepts in colorectal neoplasia. Gastroenterology 2002;123:862-876.
45. Erhardt P, Schremser EJ, Cooper GM. B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway. Mol Cell Biol 1999;19:5308-5315.
46. Ikehara N, Semba S, Sakashita M, Aoyama N, Kasuga M, Yokozaki H. BRAF mutation associated with dysregulation of apoptosis in human colorectal neoplasms. Int J Cancer 2005;115:943-950.
47. Collado M, Serrano M. The power and the promise of oncogene-induced senescence markers. Nat Rev Cancer 2006;6:472-476.
48. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005;436:720-724.
49. Minoo P, Jass J. Senescence and serration: a new twist to an old tale. J Pathol 2006;210:137-140.
50. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, et al. High frequency of BRAF mutations in naevi. Nat Genet 2003;33:19-20.
51. Uribe P, Wistuba II, Gonzalez S. BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Am J Dermatopathol 2003;25:365-370.
52. Yazdi AS, Palmedo G, Flaig MJ, Puchta U, Reckwerth A, Rutten A, et al. Mutations of the BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol 2003;121:1160-1162.
53. Bennett DC. Human melanocyte senescence and melanoma susceptibility genes. Oncogene 2003;22:3063-3069.
54. Sharpless E, Chin L. The INK4a/ARF locus and melanoma. Oncogene 2003;22:3092-3098.
55. Lin AW, Barradas M, Stone JC, van Aelst L, Serrano M, Lowe SW. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signalling. Genes Dev 1998; 12:3008-3019.
56. Torlakovic E, Snover DC. Serrated adenomatous polyposis in humans. Gastroenterology 1996;110:748-755.
57. Leggett BA, Devereaux B, Biden K, Searle J, Young J, Jass J. Hyperplastic polyposis: association with colorectal cancer. Am J Surg Pathol 2001;25:177-184.
58. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006;38:787-793.
59. Ito E, Yanagisawa Y, Iwahashi Y, Suzuki Y, Nagasaki H, Akiyama Y, et al. A core promoter and a frequent single-nucleotide polymorphism of the mismatch repair gene hMLH1. Biochem Biophys Res Commun 1999; 256:488-494.
60. Pruitt K, Ulku AS, Frantz K, Rojas RJ, Muniz-Medina VM, Rangnekar VM, et al. Ras-mediated loss of the pro-apoptotic response protein Par-4 is mediated by DNA hypermethylation through Raf-independent and Raf-dependent signalling cascades in epithelial cells. J Biol Chem 2005;280:23363-23370.
61. MacLeod AR, Rouleau J, Szyf M. Regulation of DNA methylation by the Ras signalling pathway. J Biol Chem 1995;270:11327-11337.
62. Bigey P, Ramchandani S, Theberge J, Araujo FD, Szyf M. Transcriptional regulation of the human DNA methyltransferase (dnmtl) gene. Gene 2000;242:407-418.
63. Yan T, Schupp, JE, Hwang HS, Wagner MW, Berry SE, Strickfaden S, et al. Loss of DNA mismatch repair imparts defective cdc2 signalling and G(2) arrest responses without altering survival after ionizing radiation. Cancer Res 2001;61:8290-8297.